Anti- enolase 1 (eno1) antibody and applications thereof
AssigneeAcademia Sinica
InventorsHan-Chung WU, Hsin-Jung LI
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies that bind to ENO1 and applications thereof. The applications encompass therapies and diagnostics of diseases or disorders associated with ENO1 activation and progression thereof using such antibodies. Specifically, the antibodies of the present invention bind to ENO1 on the surface of cancer cells and are useful in reducing cancer cell growth and metastasis and prolonging survival time. The antibodies of the present invention may also be used in detecting ENO1, diagnosis and prognosis of cancer and monitoring cancer progression. The present invention also provides a method for screening for a candidate agent for cancer therapy.
Claims32
An antibody or antigen-binding fragment thereof that specifically binds enolase 1 (ENO1), comprising
- (a) a heavy chain variable region (VH) which comprises a heavy chain complementary determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 2, a heavy chain complementary determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO:
- 4, and a heavy chain complementary determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO:
- 6;
- and
- (b) a light chain variable region (VL) which comprises a light chain complementary determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 9, a light chain complementary determining region (LC CDR2) comprising the amino acid sequence of SEQ ID NO:
- 11, and a light chain complementary determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO:
- 13.
-28. (canceled)
A method for screening for a candidate agent for cancer therapy, comprising
- (i) contacting an agent with a cancer cell expressing ENO1 on the cell surface of the cancer cell;
- (ii) detecting binding of the agent with ENO1 on the cell surface of the cancer cell and preferably further measuring the levels of one or more ENO1-downstream signaling events/components in the cancer cell;
- and
- (iii) determining if the agent is a candidate anti-cancer based on the results of the detection and/or measurement.
Dependencies are inferred from the claim text.